AbbVie (ABBV) Tops Q2 EPS by 15c, Issues Combined Company Guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.34, $0.15 better than the analyst estimate of $2.19. Revenue for the quarter came in at $10.43 billion versus the consensus estimate of $10.08 billion.

Full-Year 2020 Outlook:

AbbVie previously issued standalone GAAP diluted EPS guidance for the full-year 2020 of $7.60 to $7.70. AbbVie is issuing combined company GAAP diluted EPS guidance for the full-year 2020, which includes the results of Allergan from May 8, 2020 through December 31, 2020, of $4.12 to $4.22.

AbbVie previously issued standalone adjusted diluted EPS for the full-year 2020 of $9.61 to $9.71. AbbVie is issuing combined company adjusted diluted EPS guidance for the full-year 2020, which includes the results of Allergan from May 8, 2020 through December 31, 2020, of $10.35 to $10.45, representing annualized net accretion from the Allergan transaction of 11 percent. The combined company's 2020 adjusted diluted EPS guidance excludes $6.23 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

Combined company guidance supersedes previously issued standalone guidance.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• FDA: working with AbbVie (ABBV) to identify, investigate and remove suspected counterfeit Botox products found in the US
• AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
• Oilfield firm SLB's profit rises on international drilling demand